Today, shares of United Therapeutics (NASDAQ:UTHR) have crossed bullishly above their 10-day moving average of $91.48 on a volume of 152K shares. This may provide swing traders with an opportunity for a long position, as such a crossover often suggests higher prices in the near term.
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company's lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously. United's products are currently in Phase III clinical trials.
United Therapeutics (NASDAQ:UTHR) defies analysts with a current price ($91.60) 15.4% above its average consensus price target of $77.46. The stock should find initial support at its 50-day moving average (MA) of $83.55 and further support at its 200-day MA of $69.94.
In the past 52 weeks, shares of United Therapeutics have traded between a low of $36.55 and a high of $94.22 and are now at $91.60, which is 151% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has advanced 1.3%.